Net sales of $246.9 million down 15.6% year-over-year; up 2.6% on a sequential quarter basisNet loss of $9.9 million or 4.0% of net sales; adjusted EBITDA margin of 7.1%Reaffirming fiscal 2026 guidance for net sales of $900 million to $1 billion and adjusted EBITDA of $70 to $80 million CHICAGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Methode Electronics, Inc. (NYSE: MEI), a leading global supplier of custom-engineered solutions for user interface, lighting, and power distribution applications, today announced fi ...

TUCSON, Ariz., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that Patrick NJ Schnegelsberg, CEO will attend and present data on the fully implantable Emperor Total Artificial Heart (TAH) at the upcoming CSI Focus D-HF (Device Therapies in Heart Failure) conference, scheduled for December 5th thro ...

SAXONBURG, Pa., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Coherent Corp. (NYSE: COHR), a global leader in photonics, today announced a major milestone in its next-generation 300mm silicon carbide (SiC) platform to address increasing thermal efficiency demands in AI datacenter infrastructure. Coherent, a pioneer in large-diameter SiC substrates, has leveraged its proven 200mm platform expertise to develop a next-generation 300mm solution, engineered to manage rising thermal loads, that meets the accelerating perform ...

– Fourth quarter fiscal 2025 revenue up 5.9% to $138.1 million– Fiscal 2025 revenue increased 4.5% to $513.0 million– Fourth quarter fiscal 2025 operating loss decreased 48.5% to $6.8 million– Fiscal 2025 operating loss decreased 64.2% to $30.9 million– Conference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and deve ...

Core Insights - Nasdaq will present at the Goldman Sachs 2025 Financial Services Conference on December 10, 2025, at 1:00 PM ET, featuring Sarah Youngwood, Executive Vice President and CFO [1] Company Overview - Nasdaq is a leading global technology company that serves corporate clients, investment managers, banks, brokers, and exchange operators, facilitating their interaction with global capital markets and the financial system [1] - The company aims to deliver world-leading platforms that enhance liquidity, transparency, and integrity within the global economy [1] - Nasdaq offers a diverse range of data, analytics, software, exchange capabilities, and client-centric services, enabling clients to optimize and execute their business vision confidently [1]

Core Points - Soleno Therapeutics announced the passing of William G. "Bill" Harris, a long-serving member of its Board of Directors and Chairman of the Audit Committee since June 2014 [1][2] - Dr. Anish Bhatnagar, CEO and Chairman of the Board, expressed condolences and highlighted Mr. Harris's integrity and contributions to the company during challenging times [2] - Andrew Sinclair is expected to succeed Mr. Harris as Chair of the Audit Committee, qualifying as an "audit committee financial expert" as per SEC and Nasdaq rules [3] Company Overview - Soleno Therapeutics focuses on developing and commercializing novel therapeutics for rare diseases [4] - The company's first commercial product, VYKAT™ XR (diazoxide choline) extended-release tablets, was approved by the FDA on March 26, 2025, for treating hyperphagia in individuals with Prader-Willi syndrome aged 4 and older [4]

Core Viewpoint - Digital Realty, the largest global provider of cloud- and carrier-neutral data center solutions, announced the intention to redeem all outstanding 2.500% Guaranteed Notes due 2026, with a redemption date set for December 18, 2025 [1]. Group 1: Redemption Announcement - Digital Euro Finco, LLC, a wholly owned indirect finance subsidiary of Digital Realty, will redeem €1,075,000,000 aggregate principal amount of the 2.500% notes [1]. - The redemption price will be equal to par, plus accrued and unpaid interest up to the redemption date [1]. - Deutsche Trustee Company Limited serves as the trustee, while Deutsche Bank AG, London Branch acts as the paying agent for the notes [1]. Group 2: Company Overview - Digital Realty provides a comprehensive range of data center, colocation, and interconnection solutions through its global data center platform, PlatformDIGITAL® [2]. - The company operates over 300 facilities in more than 50 metropolitan areas across 25+ countries on six continents, facilitating access to connected data communities [2]. - Digital Realty's solutions support innovation in cloud and digital transformation, as well as emerging technologies like artificial intelligence (AI) [2].

Core Insights - TScan Therapeutics, Inc. will host a virtual key opinion leader event to discuss updated data from the ALLOHA Phase 1 trial and future market opportunities for its heme program [1][2] - The event will include a review of two-year relapse data from the ongoing ALLOHA Phase 1 trial evaluating TSC-101 in patients with hematologic malignancies [2] - The company has implemented an improved commercial-ready manufacturing process for the ALLOHA Phase 1 trial, which will be utilized in the upcoming pivotal trial set to begin in Q2 2026 [2] Company Overview - TScan Therapeutics is a clinical-stage biotechnology company focused on developing T cell receptor-engineered T cell therapies for cancer treatment [4] - The lead therapy candidate is aimed at preventing relapse in patients with hematologic malignancies following allogeneic hematopoietic cell transplantation [4] - The company is also developing multiple TCR-T therapy candidates for solid tumors and exploring novel targets in T cell-mediated autoimmune disorders through its TargetScan platform [4]

Total Revenues of $152.2M, up 10% year-over-year Subscription Revenues of $133.4M, up 11% year-over-yearGAAP Operating Margin of 8%, up over 800 basis points year-over-yearNon-GAAP Operating Margin of 26%, up 600 basis points year-over-year WILMINGTON, N.C., Dec. 03, 2025 (GLOBE NEWSWIRE) -- nCino, Inc. (NASDAQ: NCNO), the leading provider of intelligent, best-in-class banking solutions, today announced financial results for the third quarter of fiscal year 2026, ended October 31, 2025. "I'm extremely proud ...

ROCKVILLE, Md., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will present at the Bank of America Securities 2025 CNS Therapeutics Virtual Conference on Monday, December 8, 2025, at 3:20 p.m. ET. Investors interested in arranging a meeting with company ...